Van Putten T, May P R, Marder S R
Am J Psychiatry. 1984 Jan;141(1):16-9. doi: 10.1176/ajp.141.1.16.
The subjective response to antipsychotic medication was systematically evaluated in two samples of schizophrenic patients, one treated with haloperidol, the other with thiothixene. For both groups, a dysphoric response to the first dose was found to be a powerful predictor of noncompliance. A persisting dysphoric response was associated with a poor clinical outcome. Dysphoric responses were powerfully associated with akathisia. Patients' subjective responses were consistent throughout therapy, and there was moderate agreement between the patients' evaluation of the medication and the staff's ratings of improvement. The authors suggest that the subjective response to antipsychotic medication should not be dismissed and that dysphoric responses should be acknowledged.
在两组精神分裂症患者样本中系统评估了对抗精神病药物的主观反应,一组用氟哌啶醇治疗,另一组用硫利达嗪治疗。对于两组患者,发现对首剂药物的烦躁反应是不依从的有力预测指标。持续的烦躁反应与不良临床结局相关。烦躁反应与静坐不能密切相关。患者在整个治疗过程中的主观反应是一致的,并且患者对药物的评估与工作人员对改善情况的评分之间存在中度一致性。作者建议,不应忽视对抗精神病药物的主观反应,应认识到烦躁反应。